← Eichor
Condition: Anti Pd1 Antibody Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Anti Pd1 Antibody

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · Montefiore Medical Center · NCT06865339DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Tre
Phase 3 · 250 location(s) · AstraZeneca · NCT06989112A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
Phase 1 · 1 location(s) · L & L Bio Co., Ltd., Ningbo, China · NCT05357651Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Phase 1 · 9 location(s) · Oncomatryx Biopharma S.L. · NCT05547321A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT06642792Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acut
Phase 1/Phase 2 · 13 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05310591A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With An
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT06827236Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Phase 1/Phase 2 · 1 location(s) · Han weidong · NCT02961101A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06826768Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT05777603Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07644897Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
Phase N/A · 1 location(s) · Shanghai Zhongshan Hospital · NCT06537908Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Phase 2 · 1 location(s) · Dan Zandberg · NCT04114136Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07232654CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advance
Phase 2 · 1 location(s) · Shanghai Changzheng Hospital · NCT05585814A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Phase 1 · 7 location(s) · Light Chain Bioscience - Novimmune SA · NCT05403554Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase
Phase 2 · 1 location(s) · Fudan University · NCT07555678Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06482801Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Phase 3 · 7 location(s) · Sun Yat-sen University · NCT04778956Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06323382Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Phase 1 · 26 location(s) · Gilead Sciences · NCT05007782Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in
NA · 1 location(s) · Xijing Hospital · NCT07586891Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
Phase N/A · 1 location(s) · Shanghai Zhongshan Hospital · NCT07291063A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Phase 1/Phase 2 · 2 location(s) · NEC Bio B.V · NCT06631092IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1/Phase 2 · 3 location(s) · InxMed (Shanghai) Co., Ltd. · NCT06030258TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT06740370Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07665190Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Phase N/A · 2 location(s) · Ze-yang Ding, MD · NCT05713994
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.